|
FGFR1OP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.18199999974567E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.27340000000087E-05 |
| Normal-vs-Stage2 |
1.040860E-03 |
| Normal-vs-Stage3 |
1.97239999999432E-07 |
| Normal-vs-Stage4 |
6.09520000027786E-08 |
| Stage1-vs-Stage2 |
8.004600E-01 |
| Stage1-vs-Stage3 |
3.616300E-02 |
| Stage1-vs-Stage4 |
1.199840E-02 |
| Stage2-vs-Stage3 |
2.418800E-01 |
| Stage2-vs-Stage4 |
1.342760E-01 |
| Stage3-vs-Stage4 |
6.196000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.2904000003593E-07 |
| Normal-vs-AfricanAmerican |
3.578300E-02 |
| Normal-vs-Asian |
2.610200E-04 |
| Caucasian-vs-AfricanAmerican |
2.676800E-01 |
| Caucasian-vs-Asian |
8.749400E-01 |
| AfricanAmerican-vs-Asian |
3.838000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.21669995879171E-09 |
| Normal-vs-Female |
2.39380000000011E-05 |
| Male-vs-Female |
2.524300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.788830E-04 |
| Normal-vs-Age(41-60Yrs) |
2.4543000000099E-06 |
| Normal-vs-Age(61-80Yrs) |
8.44670000055281E-07 |
| Normal-vs-Age(81-100Yrs) |
3.635800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.432160E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.675700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.195400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.715400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.827000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.581200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.280600E-03 |
| Classical-VS-Follicular |
3.322400E-01 |
| Classical-VS-Other |
5.071200E-01 |
| Classical-VS-Normal |
2.19269999999216E-05 |
| Tall-VS-Follicular |
1.393170E-01 |
| Tall-VS-Other |
5.841600E-01 |
| Tall-VS-Normal |
4.75370000030395E-07 |
| Follicular-VS-Other |
8.290400E-01 |
| Follicular-VS-Normal |
6.20190000000242E-05 |
| Other-VS-Normal |
2.265600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.26129999964564E-07 |
| Normal-vs-N1 |
9.04640000021217E-07 |
| N0-vs-N1 |
3.362200E-01 |
|
|
